Asia Pacific Fusion Biopsy Market Size & Outlook
Asia Pacific fusion biopsy market, 2018-2030 (US$M)
Related Markets
Asia Pacific fusion biopsy market highlights
- The Asia Pacific fusion biopsy market generated a revenue of USD 129.8 million in 2023.
- The market is expected to grow at a CAGR of 9.9% from 2024 to 2030.
- In terms of segment, transrectal was the largest revenue generating biopsy route in 2023.
- Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 129.8 million |
| Market revenue in 2030 | USD 252.1 million |
| Growth rate | 9.9% (CAGR from 2023 to 2030) |
| Largest segment | Transrectal |
| Fastest growing segment | Transperineal |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transrectal, Transperineal |
| Key market players worldwide | Koninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.8% of the global fusion biopsy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 252.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fusion Biopsy Market Scope
Fusion Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific fusion biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.
Transrectal was the largest segment with a revenue share of 86.21% in 2023. Horizon Databook has segmented the Asia Pacific fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific exhibits a lucrative growth opportunity with the emerging economies at the forefront of development. The major factors driving growth of the market include rising awareness of prostate cancer, increasing population base, and rising disposable income levels as well as high unmet needs of the patients in emerging countries such as India, Japan, and China.
The growing unhealthy lifestyles in the region along with the aging population are leading to growing occurrence of various diseases and cancers. Thus, the growing demand for diagnosis within the region is expected to propel market growth.
Reasons to subscribe to Asia Pacific fusion biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific fusion biopsy market databook
-
Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific fusion biopsy market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific fusion biopsy market size, by country, 2018-2030 (US$M)
Asia Pacific Fusion Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
